PVR and neoplasm: A number of studies have demonstrated that CD155 and CD112 are overexpressed on certain hematopoietic and nonhematopoietic tumors [12]–[17], suggesting that DNAM-1 ligand expression might be induced by tumorigenesis and might stimulate CTL- and NK cell–mediated tumor immunity.